Concord Drugs Ltd - 538965 - 1St Extra-Ordinary General Meeting For FY 2022-23 To Be Held On 30.08.2022.
1st Extra-Ordinary general Meeting for FY 2022-23 to be held on 30.08.2022.06-08-2022
06-08-2022
Concord Drugs Ltd - 538965 - Outcome Of The Board Meeting Held On 06.08.2022.
Outcome of the Board Meeting held on 06.08.2022.06-08-2022
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 30.06.2022.
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2022 ,inter alia, to consider and approve Approval of unaudited financial results for the quarter ended 30.06.2022.28-07-2022
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- S Nagi ReddyDesignation :- Managing Director / Whole Time Director20-07-2022
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74 (5)20-07-2022
Concord Drugs Ltd - 538965 - Closure of Trading Window
Closure of trading window under SEBI (Prohibition of Insider Trading) Regulations, 201528-06-2022
Concord Drugs Ltd - 538965 - Related Party Disclosure Under Regulation 23(9) Of SEBI(LODR) Regulation, 2015
Related Party Disclosure under Regulation 23(9) of SEBI(LODR) Regulation, 201514-06-2022
Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Resignation of Director
Change in Directors02-06-2022
Concord Drugs Ltd - 538965 - Audited Financial Results For Quarter And Financial Year Ended 31St March, 2022.
Audited Financial Results for Quarter and Financial Year ended 31st March, 2022.30-05-2022